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LOW-DOSE-RADIATION STIMULATED NATURAL CHEMICAL AND
BIOLOGICAL PROTECTION AGAINST LUNG CANCER

B. R. Scott

䊐

Lovelace Respiratory Research Institute

䊐 Research is being conducted world-wide related to chemoprevention of future lung
cancer among smokers. The fact that low doses and dose rates of some sparsely ionizing
forms of radiation (e.g., x rays, gamma rays, and beta radiation) stimulate transient natural chemical and biological protection against cancer in high-risk individuals is little
known. The cancer preventative properties relate to radiation adaptive response (radiation hormesis) and involve stimulated protective biological signaling (a mild stress
response). The biological processes associated with the protective signaling are now better understood and include: increased availability of efficient DNA double-strand break
repair (p53-related and in competition with normal apoptosis), stimulated auxiliary apoptosis of aberrant cells (presumed p53-independent), and stimulated protective immune
functions. This system of low-dose radiation activated natural protection (ANP) requires
an individual-specific threshold level of mild stress and when invoked can efficiently prevent the occurrence of cancers as well as other genomic-instability-associated diseases. In
this paper, low, essentially harmless doses of gamma rays spread over an extended period
are shown via use of a biological-based, hormetic relative risk (HRR) model to be highly
efficient in preventing lung cancer induction by alpha radiation from inhaled plutonium.

Keywords: chemoprevention, cancer, radiation, sparsely ionizing radiation, hormesis, adaptive
response

INTRODUCTION

Lung cancer is the leading cause of cancer death worldwide and cigarette smoking is considered the major risk factor. Tobacco smoke contains a complex of chemical carcinogens as well as the alpha-particle-emitter polonium-210 (210Po). Because the population of smokers worldwide
continues to be very large, effective lung cancer preventative modalities
that can be implemented in a clinical setting for such high-risk individuals are needed. In this paper evidence is provided that low doses and dose
rates of sparsely ionizing gamma radiation and extended exposure can
efficiently prevent lung cancer among high-risk populations via stimulating and prolonging the body’s natural defenses (natural chemical and
biological prevention).
Ionizing radiation has been present in the environment since the
beginning of the universe. Radiation sources remain everywhere, including potassium-40 (40K) in our bodies and in plants and animals we ingest;
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and 40K and the uranium-238 (238U) decay chain in our homes, in the soil,
and in the air we breathe. The sun we depend on for sustaining life on
earth is also a source of ionizing radiation, as are other entities in space.
Through evolution, mammalian life forms have developed natural cancer
preventative processes (chemically and biologically regulated) that are
stimulated by low doses and dose rates of sparsely ionizing forms of radiation (e.g., x rays, gamma rays, beta particles) (Parsons 2001, 2003; Sakai
et al. 2003; Liu 2007). Low doses and dose rates of these radiations stimulate protective intercellular and intracellular signaling that leads to activated natural protection (ANP) against cancer and other genomic-instability-associated diseases (Olivieri et al. 1984; Mitchel et al. 1999; Sakai et
al. 2006; Mitchel 2007; Scott 2007a). The protective signaling appears to
be a generalized response to mild stress above an individual-specific
threshold level (Scott 2005).
Radiation ANP, which provides a biological basis for radiation hormesis as now defined (Calabrese et al. 2007), appears to be an evolutionary
benefit of the interaction of low-level ionizing radiation with mammalian
life forms on earth. Thus, ANP is evolutionarily conserved (Mitchel 2006,
2007). High radiation doses and dose rates rather than preventing cancer, inhibit the protective processes that suppress cancer (Sakai et al.
2006; Liu 2007; Scott and Di Palma 2007).
Low-Dose Radiation ANP

Low-dose radiation ANP involves induced high-fidelity DNA repair in
competition with normal apoptosis (presumably p53-dependent), activation of an auxiliary protective apoptosis-mediated (PAM) process that
selectively removes precancerous (Scott et al. 2003; Scott 2004; Portess et
al. 2007) and other aberrant cells, and also involves induced immune
functions (Feinendegen et al. 2007; Liu 2007). However, the protective
processes are transient over time intervals of hours or days, rather than
permanent effects of an exposure (Feinendegen et al. 2007).
Bauer (1995, 1996, 2000) has described what is known about the PAM
process among fibroblasts based on numerous signaling studies by his
research group using that cell type. Figure 1 relates to the description.
The protective process involves a sophisticated system of interdependencies and interactions of reactive oxygen and nitrogen species. The release
of transforming growth factor beta (TGF-β1) by transformed cells is a key
early event. Nontransformed cells, when activated, release
a novel perox–
idase (P) and nitric oxide (•NO). Superoxide anions (O•2 ) generated and
released by transformed cells participate in the intercellular signaling
and make transformed cells the selective target for intercellular induction of apoptosis (i.e., transformed cells are selectively removed via apoptosis). Chloride ions (Cl–) and hydrogen peroxide (H2O2) also participate
in the intercellular signaling. The interactions of the indicated molecules
300
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FIGURE 1. Signaling pathways for the protective apoptosis mediated (PAM) process in fibroblast
based on Bauer (1995, 1996, 2000), as redrawn by Scott and Di Palma (2007). See the main text for
a detailed explanation of the findings of Bauer (1995, 1996, 2000). Different signaling pathways to
apoptosis may apply for other cell types.

result in two currently known major signaling pathways to protective
apoptosis that are based on hypochlorous acid (HOCl)/hydroxyl radicals
(•OH) and •NO/peroxynitrite (ONOO–). H2O2 plays a key role by fostering the HOCl/•OH pathway and inhibiting the •NO/ONOO– pathway
(Bauer 2000). Additional pathways to apoptosis are likely associated with
the auxiliary PAM process (Bauer 2007), with the selected path possibly
depending on the cell type to be eliminated via apoptosis (mutants, neoplastically transformed cells, micronucleated cells, etc.), the local cellular
environment, the nature of the damage to DNA, and the stimulating
agent (Scott and Di Palma 2007).
Stochastic threshold radiation doses (which are presumed to differ
for each person and body organ/tissue) are required for ANP (Scott
2005). However, somewhat higher doses can inhibit protective signaling
(e.g., signaling related the PAM process) and also suppress the immune
system. This nonlinear continuum of dose-response is described by a Jshaped response curve (Calabrese and Baldwin 2001; Calabrese 2004,
2005; Calabrese et al. 2007).
Demonstrated Benefits of Radiation ANP

Low doses and dose rates of sparsely ionizing radiations have been
found to:
• Protect against chromosomal damage from a subsequent high dose
(Olivieri et al. 1984; Azzam et al. 1994).
• Protect against mutation induction by a high radiation dose if given
before or after the high dose (Day et al. 2006, 2007).
• Eliminate precancerous (neoplastically transformed) cells (Azzam et al.
1996; Redpath et al. 2001).
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• Prevent chemical-induced skin cancer (Sakai et al. 2003).
• Stimulate increased immune system functioning (Liu 2007; Ina and
Sakai 2005).
• Suppress lung cancer induction by alpha radiation (Sanders 2007;
Scott 2007b) and spontaneous cancers of all types (Chen et al. 2007).
• Suppress metastasis of existing cancer (Sakamoto et al. 1997; Sakamoto
2004).
• Protect against diseases other than cancer (Sakai et al. 2006).
Based on a number of years of adaptive-response research, we developed a biological-based, hormetic relative risk (HRR) model for cancer
induction (Scott 2007b; Scott and Di Palma 2007) that accounts for radiation ANP. The current version of the model is discussed in the Methods
section.
METHODS
Computational and Statistical Approaches

For fitting RR equations to lung cancer data for humans (Mayak plutonium [Pu] facility workers) exposed to alpha and gamma radiations,
Bayesian inference methods (Gelman et al. 1995; Carlin and Louis 1996;
Siva 1998) implemented via Markov chain Monte Carlo (MCMC) (Gilks
et al. 1996; Gamerman 1997) were employed with WinBUGS software
(Spiegelhalter et al. 2003), based on uniform priors for parameters to be
estimated and a very long single chain as was previously done (Scott
2007b). However, in addition to fitting RR equations to the data, predictions were made for a different baseline cancer incidence to facilitate
making comparisons to animal data. Predictions were also made for different irradiation scenarios. MCMC analyses were implemented with
WinBUGS assuming tumor cases after a given radiation exposure to have
a Poisson distribution. Radiation doses for a given dose group were
assumed to be uniformly distributed over the group.
Judgments about convergence were based on comparing the Monte
Carlo error and the posterior distribution’s standard deviation for each
free parameter. The Monte Carlo error (computed in WinBUGS) represents an estimate of the difference between the mean of the sampled values (which are used as an estimate of the mean of the posterior distribution) and the true mean of the posterior distribution. Ratios of the Monte
Carlo error for parameters to the posterior distribution standard deviation that were < 0.05 were considered consistent with convergence
(Spiegelhalter et al. 2003). Autocorrelation were also monitored during
the MCMC run to facilitate judging how long to run the chain. Where
lung cancer RR data were compared for different species (dogs, rats,
humans), they were adjusted to a common baseline incidence of 0.00095.
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Standard errors for cancer incidence were evaluated as recommended in
Fleiss (1981) when evaluating the error for a proportion. Subjective
(judgmental) upper bounds were used for reported zero cancer incidences. The bounds were set equal to one standard error for the cancer
incidence, based on 1 assigned cancer case. A subjective upper bound of
1 was also assigned to RR estimates that were calculated to be < 1, but were
not significantly different from 1.
Here, the focus is on application of the HRR model (Scott 2007b) to
lung cancer data for protracted exposure to low doses of alpha radiation
from inhaled plutonium in combination with very low doses of gamma
rays to demonstrate the highly efficient prevention of alpha-radiationinduced lung cancer by gamma-ray ANP. Alpha radiation administered
alone is a potent inducer of lung cancer. Small doses (close to natural
background radiation levels) can cause a significant increased incidence
(Sanders et al. 1976, 1977; Lundgren et al. 1991; Sanders 2007). However,
for combined exposure to low-dose alpha and low-dose gamma rays, the
gamma-ray ANP could possibly prevent cancer induction by alpha radiation. The level of protection can be quantified using the HRR model.
Hormetic Relative Risk Model

The HRR model was developed assuming proportionality between
the RR for radiation-induced cancer and the RR for radiation-induced
neoplastic transformation (Scott 2007b; Scott and Di Palma 2007). Thus,
the model is empirical (although biological-based) and is not based on
detailed mechanistic modeling of the underlying biological processes
associated radiation-induced cancer. A fundamental assumption is that
stochastic thresholds are associated with both activation and suppression
of ANP-related signaling (Scott 2005). Protective thresholds associated
with activation of protective signaling are assumed to be much lower than
the deleterious thresholds associated with suppression of protective signaling (Scott 2005). Many other models of radiation-induced harm and a
few for radiation-induced protection are also published but a survey of
these models is beyond the intended scope of this paper.
With the current version of our HRR model, the irradiated population is separated into two dose- and dose-rate dependent parts: (1) a fraction F without ANP (unprotected fraction) and (2) a fraction (1-F) that
has ANP (protected fraction). For persons with ANP, the average cancer
relative risk is given by
RRANP = (1 – PROFAC )RRLNT

(1)

where RRANP is the relative risk for persons with ANP (i.e., protected individuals) and RRLNT is the relative risk for persons without ANP and is
based on the linear-no-threshold (LNT) assumption. Risk is evaluated rel303
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ative to an unirradiated population. Bayesian methods allow evaluating
the expected proportion of the irradiated population that is protected
for a given dose and dose rate and radiation combination when formally
fitting the HRR model to data (Scott 2007b). These methods also allow
predicting the expected impacts of different radiation exposure scenarios.
The protection factor (PROFAC) takes on values from 0 to 1 and here
accounts for prevention of cancer among persons with gamma-ray ANP.
The PROFAC estimates presented in this paper are evaluated relative to
exposure to natural background radiation (conventional zero dose
group). A value PROFAC = 0.25 would indicate that cancer would be
expected to be prevented in 1 of every 4 individuals among those with
radiation ANP. For a hypothetical population containing 1000 protected
(by low-dose gamma-ray ANP) heavy cigarette smokers, if 100 were
expected to develop lung cancer because of smoking, then with a gammaray PROFAC = 0.25, 25 of the 100 would be expected to be prevented from
developing smoking-related lung cancer. Thus, not every protected person may escape lung cancer occurrence.
For alpha-radiation-induced lung cancer, relative risk can be evaluated based on a LNT function which includes the baseline cancer incidence (Scott 2007b):
RRLNT = 1 + [(1 – B)/B]KαDα ,

(2)

where B is the baseline (spontaneous) cancer incidence, Kα is the presumed always-positive slope parameter in the HRR model and Dα is the
alpha radiation absorbed dose to the target organ. Equation 1 can be
used for evaluating cancer RR for combined exposure to low-dose alpha
and gamma rays when ANP is presumed to occur for everyone while
Equation 2 can be used for exposure only to alpha radiation (no ANP
presumed). Both equations are limited to doses below those that cause
death from acute effects (Scott 2007b). The PROFAC relates only to lowdose gamma rays (or a radiation type of similar interaction characteristics
such as x rays and beta radiation when used instead of gamma rays).
The population average RR can be evaluated as the weighted average:
RR = F * RRLNT + (1 – F )RRANP .

(3)

For low-dose-rate exposure and for lung cancer, Equation 3 is expected to
apply for gamma-ray doses up to at least 2000 mGy, since gamma-ray
doses in this range were not found to contribute to an increase in lung
cancer risk under circumstances of combined exposure to alpha and
gamma radiations (Tokarskaya et al. 2002). Equations 1-3 should not be
used for the very large doses that cause death from acute effects. For
304
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moderate and high alpha radiation doses, RRLNT can be calculated to be
> 1. In such cases the results should be limited to the maximum absolute
risk of 1. For a baseline (spontaneous) cancer incidence B, the RR therefore has the constraint RR ≤ 1/B.
For combined exposure to alpha and gamma rays and when RRLNT =
1 and gamma-ray ANP occurs, Equation 3 yields the following useful
relationship:
F + (1 – F)(1 – PROFAC) = RR .

(4)

It follows from Equation 4 that if one has and estimate of both PROFAC and RR (e.g., an observed RR < 1), one can then estimate the fraction, F, of the irradiated population that is not protected (i.e., does not
have ANP) and the corresponding fraction, 1 – F, that is protected (i.e.,
has ANP). This is demonstrated in the section entitled Predicting Cancer
Incidences Assuming Kα to Be Evolutionarily Conserved.
In circumstances where one has an estimate of RRANP (based on exposure to alpha plus gamma radiation) when everyone is presumed protected and one for RRLNT (for exposure only to alpha radiation) when no
one is presumed protected, PROFAC for a given dose level Dα can be estimated using the relationship:
PROFAC = 1 – {(observed RR under alpha plus gamma irradiation)/
(observed or calculated RR under exposure only to alpha radiation)}.
A large number of crude PROFAC estimates associated with low-LET
radiation ANP against spontaneous lung cancer were recently published
based on data from many epidemiological and ecological studies
(Sanders and Scott 2007). Only limited epidemiological data are discussed in the sections that follow and do not include data related to
radon exposure. Modeling radon-induced lung cancer was beyond the
scope of this research, which has focused on exposures involving Pu isotopes alone or in combination with gamma rays (animal studies) or in
combination with gamma rays and cigarette smoke (humans).
Lung cancer data from several animal studies that involved inhaling
Pu isotopes (238Pu, 239Pu) alone or in combination with a ytterbium-169
(169Yb) label are also discussed in the next section. The gamma-ray emitting 169Yb label is widely used to facilitate monitoring how much Pu
deposits in the respiratory track during inhalation exposures. Study
designs have ensured that the gamma-ray doses from 169Yb were too low
to cause significant deleterious biological damage (Sanders et al. 1993;
Lundgren et al. 1995; Muggenburg et al. 1996). In this paper the focus is
on beneficial effects of such small gamma-ray exposures, i.e., gamma-ray
ANP against lung cancer.
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TABLE 1. Lung cancer incidence among Wistar rats that inhaled Pu-239 + Yb-169 and associated
expected (assuming no protection) and observed RR and related gamma-ray associated protection
factor against cancer based on data from Sanders (2007)
Average
Average
Alpha
Gamma
Radiation
Radiation Number of
Dose (mGy) Dose (mGy) Animals
0
56 ± 20
190 ± 90
620 ± 160

0
1
2
1

1052
1389
343
145

Lung Cancer
Incidence
0.00095 ± 0.00095
0 (0.00072)b
0 (0.0029)b
0 (0.0069)b

Expected
Relative Risk Observed
Based on
Relative
LNTa
Risk
1
20
67
216

1
0 [1]c
0 [1]c
0 [1]c

PROFAC

1.0 [0.95]d
1.0 [0.985]d
1.0 [0.995]d

a
Based on rats not exposed to gamma rays from a Yb-169 label and Equation 2 (filled circles in
Figure 2) with RR evaluated based on B = 0.00095 rather than the value of 0.00150 reported by Sanders
(2007) for rats exposed only to 239Pu alpha radiation; the calculated value for Kα is 3.3 × 10–4 mGy–1.
b
Binomial-distribution-associated standard error (SE) for frequency (Fleiss 1981) had exactly one
rat developed lung cancer, given that no cancers were observed:

SE = [ f (1 – f )/N]1/2, with f = 1/N, where N = the number of animals exposed.
c

Subjective upper bound (RR = 1).
Subjective lower bound on PROFAC based on a subjective upper bound of 1 for the observed RR;
calculated using the expected RR (column 5) as a reference, i.e., PROFAC = 1 - (1/Expected RR). This
equation is based on Equation 1.
d

RESULTS AND DISCUSSION
Estimates of PROFAC and Kα for Different Species

Table 1 shows PROFAC estimates and subjective lower bounds for lowdose, low-dose-rate, gamma-ray prevention of lung cancer among alpharadiation exposed female Wistar rats that either inhaled the alpha-emitter
239
Pu alone (in dioxide form, i.e., 239PuO2) or 239PuO2 labeled with
gamma-ray-emitter 169 Yb. The data are based on studies conducted earlier
by Sanders et al. (1976, 1993) and recently re-evaluated in the context of
gamma-ray ANP (Sanders 2007). Here, gamma-ray doses are presumed
sufficient for ANP for every rat but not high enough for its inhibition.
Also, alpha radiation doses in Table 1 are presumed not to be high enough
to overwhelm or suppress gamma-ray-induced protective signaling. The
gamma-ray doses in Table 1 are similar in magnitude to x-ray doses
received from computed tomography (Thompson and Cullom 2006).
However, for the data in Table 1, the gamma-ray exposure was protracted
over several months (physical half-life for Yb-169 = 32 d). Extending the
length of gamma-ray exposure is considered to prolong the time period
over which protective signaling occurs. This increases the efficiency of protection as has been demonstrated for eliminating precancerous cells in
vitro (Elmore et al. 2006) and was implicated for lung cancer in rats after
combined alpha and gamma irradiation (Lundgren et al. 1995).
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TABLE 2. Evidence for slope parameter Kα for lung cancer induction being similar for different
mammalian species and rodent strains.

Species or
Strain
Humans
(Kokhryakov
et al. 1996)
F344/Crl rats
(Lundgren
et al. 1991)
Wistar rats
(Sanders
et al. 1977)
Wistar rats
(Sanders
2007)
Beagle dogs
(Muggenburg
et al. 1996)

Radiation
Types
239
Pu alpha +
external gamma
239

Pu alpha +
Yb gamma

Kα in mGy–1

Equation Used

Estimated or
Implicated Value
for PROFAC

1.2 × 10–4 ± 9.0 × 10–5

Equation 1

0.86 ± 0.07

1.0 × 10–4 ± 5.0 × 10–5

Equation 2

0 (high dose
data only)a

169

238

Pu alpha

1.5 × 10–4 ± 1.3 × 10–4

Equation 2

0

239

Pu alpha

3.3 × 10–4 ± 9.5 × 10–5

Equation 2

0

Pu alpha +
Yb gamma

1.7 × 10–4 ± 1.0 × 10–5

Equation 2

0 (high dose
data only)a

238

169

a
The protective signaling induced by low-dose gamma rays is assumed to be inhibited or overwhelmed by very high doses of alpha radiation.

Calculated values for RRLNT based on fitting Equation 2 to lung cancer incidence data for rats exposed only to 239Pu (Sanders 2007) to estimate Kα (Table 2) are included in Table 1 and are based on the assumptions that no rats were protected (i.e., F = 1). The dose-group-specific
excess absolute risk per unit dose was used to obtain three estimates (for
group average doses not exceeding 780 mGy) of Kα that were then averaged to obtain Kα = 3.3 × 10–4 ± 9.5 × 10–4 mGy–1 (Table 2). This estimate
is reasonably close to the value of 1.2 × 10–4 ± 9.0 × 10–5 mGy–1 previously
reported for lung cancer in Mayak plutonium facility workers (Scott
2007b) based on Equation 1, which also includes the PROFAC. It is also
close to the value of 1.0 × 10–4 ± 5.0 × 10–5 mGy–1 previously reported for
lung cancer in F344/Crl rats that inhaled the alpha emitting aerosol
239
PuO2 (Scott 2007b), based on studies conducted by Lundgren et al.
(1991). Using the lowest two dose groups reported by Muggenburg et al.
(1996) for 238PuO2 alpha-particle-induced lung cancer in beagle dogs, a
slope parameter of 1.7 × 10–4 ± 1.0 × 10–5 mGy–1 was obtained and is consistent with the result obtained for rats and humans. Using the lowest four
dose groups reported by Sanders et al. (1977) for 238PuO2 alpha-particleinduced lung cancer in Wistar rats, a slope parameter of 1.5 × 10–4 ± 1.3
× 10–4 mGy–1 was obtained and is consistent with other estimates summarized in Table 2. For the indicated exposure groups used by Sanders et al.
(1976), group average alpha radiation doses to the lung range from 50 to
1530 mGy.
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The estimates for Kα in Table 2 for humans, rats, and dogs differ by
less than a factor of 3.5. Their un-weighted average is 1.7 × 10–4 ± 9.1 ×
10–5 mGy–1, which could be presumed to apply to rats, dogs, and humans,
and is later shown to appear to also apply to mice. Genetic polymorphisms that impact on DNA repair efficacy are expected to impact on the
parameters Kα and B but not on the PROFAC (Scott 2007b). The similar
results in Table 2 for Kα for the different genetic backgrounds suggest
that genetic polymorphisms related to DNA repair may not, however,
greatly impact Kα. For a point of reference, studies on relative susceptibility for lung cancer occurrence for pair-wise comparisons for different
genetic polymorphisms that impact on DNA repair show relative susceptibility factors < 1.5 (Hu et al. 2004; Hung et al. 2005; Benhamou and
Sarasin 2005; Schwartz et al. 2007). Genetic polymorphisms that impact
on the PAM process and immune system functioning are expected to
influence the PROFAC and B but not Kα (Scott and Di Palma 2007).
Note from Table 1 that the very small, essentially harmless protracted
gamma-ray doses (1 to 2 mGy) appear to completely prevent (PROFAC =
1.0) the occurrence of lung cancer (spontaneous and alpha-radiationinduced) for alpha radiation doses up to several hundred mGy. However,
subjective lower bounds on PROFAC presented in Table 1 would allow for
a possible lower level of protection (PROFAC as low as 0.95).
While the RR was expected to be 216 in the absence of ANP (Table
1), based on data for exposure only to alpha radiation (presumably
unprotected rats), adding an essentially harmless protracted gamma-ray
dose (1 mGy) appears to have protected against 100 % of the expected
lung cancers. Thus, all of the gamma-ray irradiated rats were apparently
very well protected from lung cancer occurrence for the alpha radiation
dose range indicated in Table 1.
Gamma-ray ANP against both alpha-radiation- and smoking-related
lung cancers in humans is implicated by the RR data in Table 3 for Mayak
plutonium facility workers chronically exposed at low rates to alpha and
gamma radiations over many years. The data in Table 3 are based on
Khokhryakov et al. (1996). The male and female workers inhaled the
alpha-emitter 239Pu and were also exposed to external gamma-ray sources
created as neutron-activation products in the workplace (Tokarskaya et al.
1997, 2002). Only alpha radiation doses were reported by Khokhryakov et
al. (1996). Gamma-ray doses were presumed negligible. Many of the male
workers were long-term heavy smokers. RR was evaluated relative to ageand gender-matched external controls, based on Russian national statistics. Variation in the baseline incidence in Table 3 relates to differences
in the age/gender structure of the different dose groups (Khokhryakov
et al. 1996).
Equation 3 was fitted to the lung cancer group average RR data in column 4 of Table 3 using WinBUGS. The expected unadjusted and adjust308
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TABLE 3. Observed and expected dose-interval-averaged lung cancer RR for Mayak plutonium
facility workers based on application of the HRR model to data from Khokhryakov et al. (1996)
Alpha
Radiation
Dose Range
(mGy)
0–12
12.1–50
51–200
201–800
801–3200

Mean
Baseline
Incidence
per 100,000a
41 ± 25
57 ± 41
76 ± 55
86 ± 93
99 ± 106

Observed
Incidence
per 100,000

Observed
Unadjusted
Average RR

Expected
Unadjusted
Average RR,
HRR Modelb

Expected
Adjusted
Average RR,
HRR Modelc

16 ± 16
30 ± 30
120 ± 68
400 ± 200
2780 ± 870

0.39 ± 0.46
0.53 ± 0.65
1.58 ± 1.45
4.65 ± 5.54
28.1 ± 31.3

0.36 ± 0.07
0.56 ± 0.09
1.59 ± 0.14
4.66 ± 0.23
28.1 ± 0.53

0.24 ± 0.07
0.40 ± 0.07
1.30 ± 0.12
4.24 ± 0.21
29.2 ± 0.55

a

Based on Russian national statistics (Khokhryakov et al. 1996)
Based on fitting the HRR model (Equation 1 used) to the data in column 4.
c
Expected (predicted) average RR based on the HRR model when the baseline B = 0.00095;
results are averaged over each dose range indicated and have not previously been reported.
b

ed RR values obtained are presented in columns 5 and 6, respectively, of
Table 3. The expected unadjusted RR values are based on the variable
baseline incidences in column 2. The expected adjusted RR values are
based on B = 0.00095. It was assumed that alpha radiation doses for each
dose group were uniformly distributed over the group-specific dose intervals indicated and that gamma-ray doses were negligible, except for their
stimulation of protective signaling (ANP). All exposed workers were
assumed to be protected (i.e., F = 0 and PROFAC > 0) by gamma-ray ANP
for the range of alpha radiation doses in Table 3. Thus, Equation 3
reduced to Equation 1, which was actually used. Being protected (i.e.,
having ANP), however, does not guarantee that cancer will be prevented
for everyone. Note that the range of alpha radiation doses over which
gamma-ray ANP is presumed to apply is up to 3200 mGy.
The MCMC analysis comprised 1 million iterations with the first
800,000 results discarded as burn-in as was previously done (Scott 2007a).
However, this time predictions were also made during the MCMC run for
a fixed baseline cancer incidence of B = 0.00095. For the variable baseline
incidences, predictions were also made about the expected impact of
excluding the alpha or the gamma radiation exposure. Predictions for
the different dose groups were based on means of posterior distributions
of the group average RR. This facilitates comparing results for humans to
animal data discussed below. Means and standard deviations of the posterior distributions of model parameters obtained were Kα = 1.2 × 10–4 ±
9.0 × 10–5 mGy–1 and PROFAC = 0.86 ± 0.07 (Table 2). These estimates are
identical to those previously reported (Scott 2007b).
For the lowest two dose groups in Table 3, the observed group average lung cancer RR values were not significantly > 0 (p > 0.05) nor were
they significantly < 1. A subjective upper bound on these group average
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FIGURE 2. Expected dose-interval-averaged RR for lung cancer based on Mayak worker data (Table
3, column 4) and the HRR model. Data are plotted vs. the group-specific, midrange alpha radiation
dose. Triangles, combined alpha + gamma irradiation (Table 3, column 5); squares, alpha radiation
only as predicted with WinBUGS; diamonds, gamma radiation only as predicted with WinBUGS. The
results for gamma radiation only were plotted vs. the corresponding alpha radiation midrange dose
because gamma-ray doses were not reported by Khokhryakov et al. (1996). Logarithmic scales are
used on both axes. The horizontal line is for RR = 1.

RR is 1 (corresponds to no change in the absolute risk), which would also
be supportive of gamma-ray ANP against alpha-radiation-induced lung
cancer, given that Kα was estimated to be 1.2 × 10–4 mGy–1. A value for Kα
> 0 implicates an increase in risk in the absence of gamma-ray ANP. The
PROFAC estimate of 0.86 ± 0.07 was previously presumed to apply to both
alpha radiation and cigarette smoke (Scott 2007b).
In the absence of gamma-ray ANP, the observed group average RR values in Table 3 would be expected to be approximately 7 times higher, as
reflected by results in Figure 2. The figure presents the MCMC predicted
dose group averages for RRLNT (squares) which are estimates of the RR
after exposure only to alpha radiation. The corresponding unadjusted
RR values from Table 3 (column 5) for combined alpha + gamma irradiation are also presented in Figure 2 (triangles). In addition, the MCMC
predicted dose group averages for RR when exposed only to gamma rays
are also presented (diamonds). Data points are not connected with lines
or curves because baselines differ for each dose group and results are
based on averaging over wide alpha radiation dose intervals. The results
in Figure 2 indicate that alpha-radiation-induced lung cancer can be prevented via gamma-ray ANP even in the dose range for which RR > 1.
Lung Cancer Dose-Response Relationships for Different Species

Figure 3 shows the lung cancer RR data for combined alpha and
gamma-ray exposure of Wistar rats (Sanders 2007) and beagle dogs
(Muggenburg et al. 1996). The Wistar rat data of Sanders (2007) for expo310
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FIGURE 3. Lung cancer RR: unadjusted RR for Wistar rats that inhaled 239Pu + 169Yb (squares) based
on data from Sanders (2007); adjusted RR for Wistar rats for inhalation exposure to only 239Pu (circles) based on data from Sanders (2007); adjusted RR for Beagle dogs (triangles) that inhaled 238Pu
based on data from Muggenburg et al. (1996); expected adjusted RR for protected adult humans
(smooth curve) exposed via inhalation to 239Pu in combination with external gamma rays, based on
Equation 3 with F = 0, PROFAC = 0.86, and Kα = 1.2 × 10–4 mGy–1; expected adjusted RR for unprotected humans (rising dashed curve) based on Equation 3 with F = 1, PROFAC = 0, and Kα = 1.2 × 10–4.
Logarithmic scales are used on both axes. Values for RR = 0 are plotted at RR = 0.01. The zero dosegroup for which RR = 1 is excluded. The lower horizontal line is for RR = 1. The upper horizontal
line is for RR = 1053. PuO2 aerosols were used in all of the animal studies.

sure only to alpha radiation are also included for comparison and to
demonstrate the dramatic protection implicated to be associated with
low-dose gamma-ray exposure when the alpha radiation dose is less than
about 1000 mGy. For the data points and model prediction in Figure 3,
RR is based on B = 0.00095. This places an upper limit of 1/0.00095 or
1053 on RR (upper horizontal line in Figure 3). It was assumed that the
PROFAC = 0 for the alpha-irradiated dogs, because of the mainly very high
radiation doses involved. Similarly PROFAC was assumed equal to zero for
Wistar rats exposed only to alpha radiation.
Note that the adjusted RR in Figure 3 seemed to converge for the different species and approach an asymptotic value below the upper limit of
1053 as the alpha radiation dose increased above 10,000 mGy. The mainly very high alpha radiation doses received by dogs (500 to 340,000 mGy)
appear to have completely inhibited or overwhelmed protective signaling
associated with gamma-ray ANP. The simulated smooth curve in Figure 3
is for protected adult humans and is based on Equation 3 with F = 0, Kα
=1.2 × 10–4 mGy–1 and PROFAC = 0.86. The upper dashed curve in Figure
3 is for exposure only to alpha radiation and applies to unprotected adult
humans and was obtained by setting F = 1, Kα = 1.2 × 10–4 mGy–1, and PROFAC = 0 in Equation 3. In this case, Equation 3 reduces to RRLNT.
Alpha radiation doses > 2000 mGy appeared to have inhibited protective signaling (e.g., related to the PAM process) for rats and dogs based
on the convergence of the dose-response data (for protected and unpro311
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tected groups) at high doses. Humans were presumed to be protected
against alpha radiation doses up to 3200 mGy, based on results presented
in Table 3.
Gamma-Ray ANP for Humans vs. Rats

Protection provided to humans and Wistar rats by low-dose/low-doserate gamma-ray ANP can be assessed relative to the rising dashed curve
(humans) and filled circles (Wistar rats) in Figure 3 that relate to only
alpha radiation exposure. Humans (smooth curve) appear to be somewhat less protected than were Wistar rats (filled squares). However, RR
uncertainty for humans is quite large (Table 3, column 4) and the RR for
humans cannot be stated with confidence to be different than from
Wistar rats.
The data for Wistar rats exposed to both alpha and gamma rays in
Figure 3 (filled squares) show a very steep increase in RR for doses above
about 1000 mGy. This suggests that alpha radiation doses above about
1000 mGy may have suppressed or inhibited gamma-ray ANP in some of
the rats. This dose zone of rapidly increasing RR has been called
Transition Zone B (Scott 2007a,b). It is the dose zone where stochastic
thresholds for inhibition/suppression of ANP occur. Transition Zone A
occurs at very low doses and is the dose zone where stochastic thresholds
for ANP occur. The dose zone that is between Transition Zone A and
Transition Zone B is called the Zone of Maximal Protection. For the Zone
of Maximal Protection, everyone is presumed to have ANP (i.e., F = 0).
The boundaries for the indicated three zones are presumed to depend
on dose-rate and the types of radiation involved (Scott 2005, 2007b).
The results in Figure 3 are consistent with the view that low doses and
dose rates of gamma rays activate the body’s natural defenses (biological
and chemical protection), which in turn can significantly reduce the risk
of cancer from exposure to carcinogenic doses of other agents. Similar
results have been demonstrated for suppression of chemically-induced
cancer via low-dose-rate exposure to sparsely ionizing radiation (Mitchel
et al. 1999; Sakai et al. 2003). For alpha radiation doses > 10,000 mGy in
Figure 3, there is no evidence for gamma-ray ANP for rats and dogs. This
suggests that deleterious biological signaling associated with very high
alpha radiation doses may overwhelm or suppress protective signaling in
rats, dogs, and humans that is associated with gamma-ray ANP.
Predicting Cancer Incidences Assuming Kα to Be Evolutionarily Conserved

The similar estimates in Table 2 for Kα for humans, rats, and dogs suggest that Kα may be evolutionarily conserved for mammals. If so, the average of the values in Table 2 (1.7 × 10–04 mGy–1) could then be used to predict the expected tumor incidence in other mammalian species (e.g.,
312
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mice). To investigate this possibility, the indicated value for Kα and an
observed spontaneous (baseline) lung cancer incidence of 0.0198 for 84day old female C57BL/6J mice (Lundgren et al. 1987) has been used with
Equation 1 (re-expressed as an absolute risk) to predict the expected
lung cancer incidence in the mice after they were exposed to 239PuO2
(with a 169Yb label). Group-specific average alpha radiation doses to the
lung were reported to be 1,200, 2,800, and 14,000 mGy for the three lowest exposed groups (Lundgren et al. 1987). Using PROFAC = 0.93 (average of estimates for Mayak workers [0.86] and Wistar rats [1.0]) led to
predicted incidences of 0.016, 0.035, and 0.07 in comparison to the
observed incidences of 0.029, 0.047, and 0.051, respectively. Predicted
and observed values differed by less than a factor of 2. Thus, under the
assumption that Kα is evolutionarily conserved for mammals, the predicted incidences are roughly consistent with those that were observed.
Using the same approach and the spontaneous lung cancer incidence
of B = 0.00095 for the female Wistar rats in Table 1, one can predict the
expected lung cancer incidence for the higher dose of 2,320 mGy that
was used by Sanders (2007). The predicted incidence is (1-0.93)*(1) =
0.07. Here “(1)” is the maximum incidence possible under the LNT
absolute risk function. The observed lung cancer incidence was 0.069
(Sanders 2007). The next higher dose used by Sanders was much higher
(5,030 mGy). This dose appeared to suppress ANP in some of the Wistar
rats in that the observed lung cancer incidence was 0.21 when the expected incidence based on PROFAC = 0.93 and Kα = 1.7 × 10–4 mGy–1 was 0.07
using Equation 1 (i.e., assuming F = 0). With PROFAC = 0, the expected
lung cancer incidence is 1.0 for the indicated dose. Thus, the data suggests that some but not all of the rats had gamma-ray ANP suppressed or
that the high doses used may have caused significant life shortening due
to acute effects. Assuming the fraction F of the rats had suppressed/inhibited gamma-ray ANP and no significant life shortening occurred, F is
given by the solution to (see Equation 4)
F + (1 – F) * (1 – PROFAC) = 0.21.
Substituting PROFAC = 0.93 and solving for F, one obtains F = 0.15
(i.e., 15% not having ANP). This implicates 85% of the irradiated group
having a lung cancer frequency of 0.07 (= 1 – PROFAC) and the remaining 15% as having a frequency of 1.
The results obtained support the suggestion that Kα may be evolutionarily conserved for mammals. Many published radionuclide inhalation toxicity studies using alpha-emitting isotopes also used 169Yb labels to
monitor deposition of aerosol in the respiratory tract. Data from such
studies should be re-examined for evidence for gamma-ray ANP. Further,
absolute risk estimates for alpha-radiation-induced lung cancer based on
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such studies may be substantially underestimated for alpha radiation
doses below about 100 mGy, when extrapolating from data for doses
between 100 – 1,000 mGy using the LNT model.
Influence of Age at Exposure on Lung Cancer Risk

Lundgren et al. (1995) also examined the influence of age at exposure on the incidence of alpha-radiation-induced lung cancer among
F344/Crl rats that inhaled 239PuO2 along with a 169Yb label. Interestingly,
unlike for 84-day old rats whose cancer incidence increased as radiation
dose increased, for 450-day old rats, a hormetic-type response was implicated for a group average alpha radiation dose of 880 mGy to the lung
(Lundgren et al. 1995). Such observations are consistent with the view
that PROFAC may increase with age (Scott and Di Palma 2007). If so, children may not benefit as much as adults from gamma-ray ANP.
Implications for Other Radiations

Because they are sparsely ionizing, gamma rays, x rays, and beta radiation have similar physical characteristics with respect to their interactions with biological tissue. Thus, extended exposures to essentially harmless low doses of any of these sparsely ionizing radiations would also be
expected to efficiently stimulate protective signaling associated with ANP
against lung cancer.
Possible Modalities for Lung Cancer Prevention

The PAM process when activated by sparsely ionizing radiation
removes precancerous cells via selective apoptosis (Scott 2004; Bauer
2007; Portess et al. 2007). Cells transformed by a variety of carcinogens
(including chemical carcinogens, UV light plus TGF-β, oncogenic retroviruses, herpes simplex virus, or viral oncogenes such as ras and src) were
found to be equally sensitive to the PAM process (Jürgensmeier et al.
1994; Bauer 1996). Low-dose-rate gamma irradiation has been demonstrated to suppress skin cancer induction by methylcholanthrene (Sakai
et al. 2003) and lung cancer induction by alpha radiation (Figures 2 and
3). Methylcholanthrene and alpha radiation from 210Po are known risk
factors for lung cancer that are present in cigarette smoke.
What are the possible modalities of lung cancer prevention among
high-risk smokers who have failed to heed smoking-cessation advice or
other interventions such as exercise programs? Other than social and
medical interventions to encourage smoking cessation, possible treatments would involve medically-supervised sparsely-ionizing radiation
ANP. Repeated very small x-ray doses could be administered over and
extended period from equipment in hospitals used for administering
diagnostic x rays. Special radiation ANP rooms with elevated background
314

https://scholarworks.umass.edu/dose_response/vol6/iss3/7

16

Scott: Stimulated natural protection against lung cancer

Stimulated natural protection against lung cancer

gamma radiation could be used in medical facilities for implementing
natural protection from a future lung cancer. Induced natural protection
could also be provided against other types of cancer.
Most children are unlikely to be at high-risk for cancer. Thus, using
low-dose-radiation ANP to prevent cancer among children may be inappropriate in most cases. Many other agents are also being studied related
to possibly preventing lung and other cancers among high risk populations and individuals (Sporn and Suh 2000). It may be beneficial to consider combining low-rate, low-dose, low-LET radiation exposure with
other cancer preventative agents or exercise-based induction of adaptive
response (Ji et al. 2006; Sonneborn and Barbee 1998).
CONCLUSIONS

The results presented demonstrate that low doses of gamma rays
when spread over time are a potent inducer of natural chemical and biological protection against lung cancer. Because gamma rays, x rays, and
beta radiation have very similar physical characteristics related to their
interaction with biological tissue, low x-ray and beta-radiation doses when
spread over time (e.g., repeated very low doses of x rays, or continuous
very-low levels of beta irradiation) are also expected to be potent inducers of natural chemical and biological protection against lung cancer.
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